The Dow Chemical Company and Cambrex have completed and opened the operational facility for Dow’s Hydroxypropyl Methylcellulose Acetate Succinate (HPMCAS) for Drug Solubility Enhancement. The facility is an expansion of   Cambrex’s Karlskoga site, and work began in early 2013. The facility completion and start of HPMCAS product validation marks a year-long process that began with a solubilization partnership between Dow and Bend Research, announced in October 2012. Starting early 2014, Do...